Palynziq

Active Ingredient(s): Pegvaliase-pqpz
FDA Approved: * May 24, 2018
Pharm Company: * BIOMARIN PHARM
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Recent Palynziq Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pegvaliase-pqpz
  • Injection: 10mg/0.5ml, 2.5mg/o.5ml, 20mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Palynziq: (3 results)

Sorted by National Drug Code
  • 68135-058 Palynziq 2.5 mg/.5ml Subcutaneous Injection, Solution by Biomarin Pharmaceutical Inc.
  • 68135-673 Palynziq 20 mg/ml Subcutaneous Injection, Solution by Biomarin Pharmaceutical Inc.
  • 68135-756 Palynziq 10 mg/.5ml Subcutaneous Injection, Solution by Biomarin Pharmaceutical Inc.

Other drugs which contain Pegvaliase-pqpz or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2018 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 19 July 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.